Lantern Pharma

General Information
Business:

 

We are a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies. Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our A.I. platform and our biomarker driven approach. Our A.I. platform, known as RADR®, currently includes more than 275 million data points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 7
Founded: 2013
Contact Information
Address 1920 McKinney Avenue, 7th Floor, Dallas, TX 75201, US
Phone Number (972) 277-1136
Web Address http://www.lanternpharma.com
View Prospectus: Lantern Pharma
Financial Information
Market Cap $96.5mil
Revenues $0 mil (last 12 months)
Net Income $-2.45 mil (last 12 months)
IPO Profile
Symbol LTRN
Exchange NASDAQ
Shares (millions): 1.6
Price range $15.00 - $17.00
Est. $ Volume $25.0 mil
Manager / Joint Managers ThinkEquity (a division of Fordham Financial Management)
CO-Managers Dougherty & Company/ Paulson Investment Company
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change